These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3910317)

  • 21. Expression of MHC class II antigens on bile duct epithelium in experimental graft versus host disease.
    Takács L; Szende B; Rot A; Diamanstein T
    Clin Exp Immunol; 1985 Jun; 60(3):449-56. PubMed ID: 4040446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transition of T cell receptor gamma/delta expressing double negative (CD4-/CD8-) lymphocytes after allogeneic bone marrow transplantation.
    Yabe M; Yabe H; Hattori K; Hinohara T; Morimoto T; Kato S; Kusunoki A
    Bone Marrow Transplant; 1994 Nov; 14(5):741-6. PubMed ID: 7889006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human herpes virus-6 infection in marrow graft recipients: role in pathogenesis of graft-versus-host disease. Newcastle upon Tyne Bone Marrow Transport Group.
    Appleton AL; Sviland L; Peiris JS; Taylor CE; Wilkes J; Green MA; Pearson AD; Kelly PJ; Malcolm AJ; Proctor SJ
    Bone Marrow Transplant; 1995 Dec; 16(6):777-82. PubMed ID: 8750269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
    Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
    Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients.
    Hägglund H; Boström L; Remberger M; Ljungman P; Nilsson B; Ringdén O
    Bone Marrow Transplant; 1995 Dec; 16(6):747-53. PubMed ID: 8750264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The putative role of HLA-C recognition in graft versus host disease (GVHD) and graft rejection after unrelated bone marrow transplantation (BMT).
    Bishara A; Amar A; Brautbar C; Condiotti R; Lazarovitz V; Nagler A
    Exp Hematol; 1995 Dec; 23(14):1667-75. PubMed ID: 8542963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring systemic donor lymphocyte macrochimerism to aid the diagnosis of graft-versus-host disease after liver transplantation.
    Taylor AL; Gibbs P; Sudhindran S; Key T; Goodman RS; Morgan CH; Watson CJ; Delriviere L; Alexander GJ; Jamieson NV; Bradley JA; Taylor CJ
    Transplantation; 2004 Feb; 77(3):441-6. PubMed ID: 14966423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Expression of adhesion molecules in hepatic graft-versus-host disease].
    Hayashishita N
    Hokkaido Igaku Zasshi; 1994 May; 69(3):627-37, 639. PubMed ID: 7927186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease.
    Abrahamsen IW; Sømme S; Heldal D; Egeland T; Kvale D; Tjønnfjord GE
    Haematologica; 2005 Jan; 90(1):86-93. PubMed ID: 15642674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Liver biopsy in the management of liver dysfunction after allogeneic hematopoietic stem-cell transplantation].
    Chen H; Huang XJ; Liu KY; Xu LP; Wang H; Liu DH; Lu J; Lu DP
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3062-6. PubMed ID: 16324408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
    Xun CQ; Thompson JS; Jennings CD; Brown SA
    Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Skin biopsies for early diagnosis and prognosis of graft-versus-host disease in recipients of allogeneic stem cells from blood or bone marrow.
    Heldal D; Brinch L; Evensen SA; Tjønnfjord GE; Aamodt G; Elgjo K; Sviland L
    Bone Marrow Transplant; 2004 Aug; 34(4):345-50. PubMed ID: 15170163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular composition of the spleen after human allogeneic bone marrow transplantation.
    Dilly SA; Sloane JP
    J Pathol; 1988 Jun; 155(2):151-60. PubMed ID: 3292736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic intestinal graft-versus-host disease: clinical, histological and immunohistochemical analysis of 17 children.
    Patey-Mariaud de Serre N; Reijasse D; Verkarre V; Canioni D; Colomb V; Haddad E; Brousse N
    Bone Marrow Transplant; 2002 Feb; 29(3):223-30. PubMed ID: 11859394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marked increase of CD8+S6F1+ and CD8+CD57+ cells in patients with graft-versus-host disease after allogeneic bone marrow transplantation.
    Fukuda H; Nakamura H; Tominaga N; Teshima H; Hiraoka A; Shibata H; Masaoka T
    Bone Marrow Transplant; 1994 Feb; 13(2):181-5. PubMed ID: 7515741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.